Japanese pharmaceutical firm Takeda has announced a global collaboration and license agreement with US-based Halozyme Therapeutics, Inc., granting Takeda exclusive access to Halozyme’s innovative ENHANZE® drug delivery technology for use with vedolizumab.
This partnership underscores Takeda’s commitment to advancing patient care and unlocking new possibilities for vedolizumab, which is marketed under the trade name ENTYVIO®. Entyvio is approved for the treatment of adult patients with moderately to severely active ulcerative colitis and Crohn's disease.
Ulcerative colitis and Crohn’s disease, the two most prevalent forms of inflammatory bowel disease (IBD), are chronic, complex, and unpredictable conditions. Each patient’s journey is unique, often requiring multiple treatment approaches over time. With IBD prevalence projected to surpass 10 million globally by 2032, Takeda recognizes the urgent need for ongoing innovation. This collaboration demonstrates Takeda’s continued commitment to directly address these challenges, expand its GI and Inflammation portfolio and broaden access to vedolizumab worldwide.
Under the terms of the agreement, Takeda will provide Halozyme with an upfront payment, as well as potential future development and commercial milestone payments. Halozyme will also be eligible to receive royalties on sales of products containing vedolizumab in combination with ENHANZE®.
Halozyme’s proprietary ENHANZE® drug delivery technology is the leading recombinant human hyaluronidase PH20 enzyme (rHuPH20) and has touched more than one million patient lives through ten commercialized products across over 100 global markets.
